Leiden University Medical Center

Enara Bio highlights Dark Antigens™ as a novel class of targets for developing targeted immunotherapies against solid tumors

Retrieved on: 
Monday, November 7, 2022
Dark, Boehringer Ingelheim, Company, Research, TCR, 2021 Essex County Council election, NSCLC, Leiden University Medical Center, Copenhagen Denmark Temple, RA, Large-cell lung carcinoma, Immunotherapy, Francis Crick Institute, NSC, Cancer, Genome, Partnership, National Centre for Text Mining, Melanoma, Enara López, SITC, Patient, Vaccine

OXFORD, England, Nov. 7, 2022 /PRNewswire/ -- Enara Bio, a biotechnology company advancing novel T cell directed immunotherapies against unconventional, shared, cancer-specific antigens, today announces it will present two posters at the 37th Society for Immunotherapy of Cancer Annual Meeting, which will be held in Boston, MA and virtually, 8-12 November 2022.

Key Points: 
  • The two abstracts describe the pioneering research being conducted by Enara Bio and its partners, leveraging its expertise and unique EDAPT platform.
  • These findings demonstrate Enara Bio's ability to identify Dark Antigens shared across a broad range of cancers enabling the development of novel immunotherapies, such as bispecific T cell engagers, adoptive cell therapies and cancer vaccines.
  • Dark Antigens represent a vast untapped resource of novel, shared, homogenously expressed cancer-specific targets from a broad range of solid tumor types.
  • Enara's proprietary EDAPT platform enables the discovery of Dark Antigens, a novel source of shared, tumor-specific T cell targets derived from genomic dark matter.

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Retrieved on: 
Friday, November 4, 2022
Holm–Bonferroni method, Subclinical infection, Immune tolerance, Ageing, Asthma, Infection, Chronic kidney disease, DFU, Idiopathic pulmonary fibrosis, Pakistan Library Automation Group, Ethics, Internal medicine, Cytokine release syndrome, FDA, Safety, Incidence, ASX, Potency (pharmacology), Sepsis, Ulcer, Therapy, Leiden University Medical Center, Stem cell, Graft-versus-host disease, Acute respiratory distress syndrome, Transplant, Microsoft, Kidney transplantation, Regenerative medicine, US, MCA, Clinical trial, LUMC, MSC, Risk, Efficacy, Kidney, Survival, Patient, Osteoarthritis, Cancer, Department, Dialysis, Pharmaceutical industry, Dentistry

MELBOURNE, Australia, Nov. 4, 2022 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.

Key Points: 
  • Kidney transplantation is life-saving in patients with chronic renal failure and frees the patient from the need for dialysis.
  • The clinical trial, entitled the "Safety and Efficacy of iPSC-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients - the Nereid Study", will be led by Prof.
  • "This exciting new collaboration follows very promising clinical trial data with MSCs published by Professor Rabelink[1] and our own published pre-clinical data[2] in organ transplant rejection.
  • The consistency and potency of Cynata's unique iPSC-derived Cymerus MSCs make them an ideal candidate for this clinical trial."

Dutch DC4U and LUMC consortium receive €1.7 million Eurostars grant to jointly develop an innovative treatment of Type I diabetes

Retrieved on: 
Tuesday, October 25, 2022
Spinoza Prize, Allergy, D3, CSO, Disease, Head, LUMC, Autoimmune disease, Stroke, Vaccine, IPS, Degenerative disease, Kidney failure, Type 1 diabetes, DC, Patient, B cell, Insulin, Investor, Research, Cell, Leiden University Medical Center, Severe cognitive impairment, Knowledge, Goal, Baruch Spinoza, Immune system, Sugar, Immunopathology, TUD, Survival, Intervention, European Commission, Pharmaceutical industry, Eurostar, Langerhans

Type 1 diabetes is a serious autoimmune disease that originates when cells that make insulin (beta cells) are attacked by the immune system.

Key Points: 
  • Type 1 diabetes is a serious autoimmune disease that originates when cells that make insulin (beta cells) are attacked by the immune system.
  • Type 1 diabetes affects more than 8 million people worldwide and can result in serious side effects including kidney failure, heart disease, stroke, foot ulcers, blindness and early death.
  • Eurostars helps (small) companies to install market-oriented technological development and aims to shorten the time-to-market of new technologies and reduce technical risks.
  • For more info on Eurostars please visit: www.eurekanetwork.org/countries/netherlands/Eurostars/
    DC4U is a preclinical life science company developing treatments for autoimmune diseases and allergies.

Dutch DC4U and LUMC consortium receive €1.7 million Eurostars grant to jointly develop an innovative treatment of Type I diabetes

Retrieved on: 
Tuesday, October 25, 2022
Spinoza Prize, Allergy, D3, CSO, Disease, Head, LUMC, Autoimmune disease, Stroke, Vaccine, IPS, Degenerative disease, Kidney failure, Type 1 diabetes, DC, Patient, B cell, Insulin, Investor, Research, Cell, Leiden University Medical Center, Severe cognitive impairment, Knowledge, Goal, Baruch Spinoza, Immune system, Sugar, Immunopathology, TUD, Survival, Intervention, European Commission, Pharmaceutical industry, Eurostar, Langerhans

Type 1 diabetes is a serious autoimmune disease that originates when cells that make insulin (beta cells) are attacked by the immune system.

Key Points: 
  • Type 1 diabetes is a serious autoimmune disease that originates when cells that make insulin (beta cells) are attacked by the immune system.
  • Type 1 diabetes affects more than 8 million people worldwide and can result in serious side effects including kidney failure, heart disease, stroke, foot ulcers, blindness and early death.
  • Eurostars helps (small) companies to install market-oriented technological development and aims to shorten the time-to-market of new technologies and reduce technical risks.
  • For more info on Eurostars please visit: www.eurekanetwork.org/countries/netherlands/Eurostars/
    DC4U is a preclinical life science company developing treatments for autoimmune diseases and allergies.

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

Retrieved on: 
Friday, October 14, 2022
Molecule, LSD, Chronic cough, N,N-Dimethyltryptamine, Chronic kidney disease, DMT, Stroke, Science, IPF, Animal, Policy, Ethics, Family, DMT: The Spirit Molecule, Patient, Drug development, Brain, Music, Leiden University Medical Center, AGN, Neurogenesis, Trial of the century, Company, Ketamine, Industry, Constraint-induced movement therapy, CSE, Rehabilitation, Psilocybin, GLOBE, Clinical trial, Keynote, Pharmacy, Human, Pharmaceutical industry

Algernon recently announced that it became the Headline Sponsor for the Wonderland conference to be held in Miami from November 3rd to the 5th, 2022.

Key Points: 
  • Algernon recently announced that it became the Headline Sponsor for the Wonderland conference to be held in Miami from November 3rd to the 5th, 2022.
  • Algernon is very fortunate to have Dr. Rick Strassman as a key opinion leader on our DMT stroke research program, said Moreau.
  • Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs.
  • Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.

AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022

Retrieved on: 
Monday, September 12, 2022
Giant, Disability, Therapy, Safety, Infection, Incidence, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Risk, FDA, TGCT, CSF1, Palliative care, Health, Macrophage, Patient, Cancer, Physician, Oncology, Pain, Quality of life, Licensed practical nurse, Cell, Tenosynovial giant cell tumor, Professor, Diagnosis, Fast Track, GLOBE, CSF1R, PD, Leiden University Medical Center, ESMO, Pharmaceutical industry, Vaccine

The favorable results confirmed high local concentrations and pharmacologic activity at the tumor site that were sustained beyond the dosing period.

Key Points: 
  • The favorable results confirmed high local concentrations and pharmacologic activity at the tumor site that were sustained beyond the dosing period.
  • AmMax Bio is scheduled to present final positive efficacy data from the study at a scientific conference later this fall.
  • Under an exclusive worldwide license from Amgen, Inc., AmMax is leveraging positive proof-of-concept data and an improved safety profile to advance AMB-05X into the next phase of its clinical development program for tenosynovial giant cell tumor (TGCT).
  • AmMax actively seeks to in-license potentially best-in-class oncology products in areas of significant unmet medical need.

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Retrieved on: 
Monday, September 12, 2022
Molecule, Leiden University Medical Center, Leiden University, Time, Safety, Trial of the century, Human, Ethics, Ketamine, University, LSD, DMT: The Spirit Molecule, Dream, Neurology, Company, Imperial College London, CHDR, Psilocybin, Growth, LUMC, Partnership, Stroke, Leiden Bio Science Park, Psychosis, IVF, Patient, Clinical trial, CSE, N,N-Dimethyltryptamine, AGN, Neurogenesis, Consciousness, Heart, Niacin, Pharmacokinetics, Pharmacy, Rehabilitation, GLOBE, DMT, Animal, Constraint-induced movement therapy, GMP, Brain, Pharmaceutical industry

Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study.

Key Points: 
  • Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study.
  • Christopher J. Moreau CEO of Algernon Pharmaceuticals further commented saying, We look forward to getting our DMT clinical stroke program started with our Phase 1 study at CHDR in the Netherlands, said.
  • Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke.
  • The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.

Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor

Retrieved on: 
Thursday, September 8, 2022
Human, CSE, Safety, Pharmacokinetics, CEO, Psilocybin, Friends, Awareness, Leiden University Medical Center, Disease, Music, Rehabilitation, Policy, Brain, DMT, Ethics, FSE, Neurogenesis, Science, IVF, Ketamine, Animal, Medicine, Stroke, Company, Station North Arts and Entertainment District, Pharmacy, CHDR, N,N-Dimethyltryptamine, Clinical trial, AGN, Constraint-induced movement therapy, Entertainment district, Industry, LSD, Patient, Nightclub, Pharmaceutical industry, Algernon

Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland, the world-leading event in the psychedelic medicine industry.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland, the world-leading event in the psychedelic medicine industry.
  • "We are delighted to welcome our friends at Algernon Pharmaceuticals as a sponsor of the conference and to have them involved with our programs," said Patrick Moher, President of Microdose Psychedelic Insights.
  • "Wonderland Miami is a one-of-a-kind event, and we are very pleased to continue our collaboration with Algernon Pharmaceuticals as an official headline sponsor."
  • "We are delighted to be the headline sponsor for the Wonderland 2022 event and have the opportunity to build a greater awareness of Algernon and our DMT stroke research program within the many different facets of the psychedelic medicine world," said Christopher J. Moreau, CEO, Algernon Pharmaceuticals.

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

Retrieved on: 
Thursday, September 8, 2022
Human, CSE, Safety, Pharmacokinetics, Psilocybin, Friends, Awareness, Leiden University Medical Center, Disease, Music, Rehabilitation, Policy, Brain, DMT, Ethics, Neurogenesis, Science, Ketamine, Animal, GLOBE, Medicine, Stroke, Company, Pharmacy, N,N-Dimethyltryptamine, Clinical trial, AGN, Constraint-induced movement therapy, Industry, LSD, Patient, Pharmaceutical industry

We are delighted to welcome our friends at Algernon Pharmaceuticals as the lead sponsor of the conference and to have them involved with our programs, said Patrick Moher, President of Microdose Psychedelic Insights.

Key Points: 
  • We are delighted to welcome our friends at Algernon Pharmaceuticals as the lead sponsor of the conference and to have them involved with our programs, said Patrick Moher, President of Microdose Psychedelic Insights.
  • Wonderland Miami is a one-of-a-kind event, and we are very pleased to continue our collaboration with Algernon Pharmaceuticals as an official headline sponsor.
  • Microdose Psychedelic Insights aims to unlock the potential of psychedelic medicine through Industry events, market intelligence, original, evidence-based content, strategy, and community.
  • Fostering creative and professional growth, Wonderland: Miami is the premier destination for the psychedelic medicine industry.

Professor Melief to receive 2022 Pedro J. Romero Service to JITC Award from Society for Immunotherapy of Cancer

Retrieved on: 
Thursday, September 8, 2022
Regeneron Pharmaceuticals, Cancer, Immunotherapy, SLP, HPV, PRAME, YouTube, ISA, Leiden University Medical Center, Academy, Infection, 2021 PSA Annual Awards, LinkedIn, Science, HPV16, Cell, Patent, CSO, JITC, Immunology, Annual general meeting, Fast Track, Company, Immune system, News, Twitter, Founder, Facebook, OPC, Society for Immunotherapy of Cancer, Society, Patient, SITC, Pharmaceutical industry, Vaccine

This Award recognizesindividuals who made immeasurable contributions and demonstrated outstanding commitment to theJournalfor Immunotherapy of Cancer (JITC) the official journal of the SITC.

Key Points: 
  • This Award recognizesindividuals who made immeasurable contributions and demonstrated outstanding commitment to theJournalfor Immunotherapy of Cancer (JITC) the official journal of the SITC.
  • The award will be presented at the SITC's 37th Annual Meeting in Boston, 8-12 November 2022.
  • This award announcement follows the news that Professor Melief will be inducted as a Fellow of the Academy of Immuno-Oncology (FAIO), one of the SITC's most prestigious honors.
  • Professor Melief is a globally recognized immunology expert, specializing in cancer immunology and immunotherapy.